SAN DIEGO - DNA medicine developer Seawolf Therapeutics emerged from stealth on Nov. 16, 2026, with $100 million in financing and a Sanofi collaboration worth up to $1.2 billion.
Venture Backing and Sanofi Partnership
Versant Ventures, MPM BioImpact, and Novartis Venture Fund led the $100 million seed and Series A rounds, joined by Eli Lilly and CRISPR Therapeutics. Under the multi-target exclusive license deal, Sanofi will collaborate initially on bleeding disorders and undisclosed conditions, offering Seawolf an undisclosed upfront payment, up to $1.2 billion in milestones, and tiered royalties.
Non-Viral DNA Delivery Platform
Seawolf's TRIDENT technology packages engineered DNA inside lipid nanoparticles—the same delivery vehicle used in mRNA vaccines—paired with an auxiliary factor that ferries genetic cargo into cell nuclei. Unlike traditional virus-based gene therapies, the company says its non-viral platform allows repeat dosing while sustaining longer-lasting protein expression than RNA drugs. Preclinical primate studies showed well-tolerated expression, though results remain unpublished in peer-reviewed journals.
Metabolic Pipeline and Trial Timeline
In-house, Seawolf is testing an animal-stage metabolic program designed to build muscle and reduce fat for potential use against obesity, muscle loss, and osteoporosis. Chief Executive Elizabeth Alcamo said the company aims to select a development candidate by late 2027 and file for human clinical trials by the end of 2028, noting additional capital will likely be needed.



